The identification of TSP4 and extracellular vesicle-associated proteins as potential minimally invasive biomarkers provides a framework for biochemical monitoring of PURA syndrome. This evidence concerns the gene THBS4 and PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation.